NIOSHTIC-2 Publications Search - 20037693 - Registering multiple primary tumors in central cancer registries.
Coding rules for multiple primary tumors are complex and may diminish data reliability. The purpose of this study was to assess the reliability and utility of reports of multiple primary cancers among breast cancer cases. A NAACCR dataset for tumors diagnosed from 1994 - 1998 was used. Within each registry, all tumors were linked by patient identification number to determine the history of primaryhttps://www.cdc.gov/niosh/nioshtic-2/20037693.html
18F-FDG PET-Detected Synchronous Primary Neoplasms in the Staging of Esophageal Cancer: Incidence, Cost, and Impact on...
F-Fluorodeoxyglucose positron emission tomography (F-FDG PET) imaging is increasingly the standard of care in the staging of esophageal cancer. Synchronous neoplasms may be identified, and this study evaluated the prevalence of such tumors and theirhttp://www.biomedsearch.com/nih/18F-FDG-PET-Detected-Synchronous/23154472.html
Multiple primary malignant neoplasms series: Recent results in cancer research B.S. Schoenberg Springer-Verlag, Berlin-New York...
Multiple primary malignant neoplasms series: Recent results in cancer research B.S. Schoenberg Springer-Verlag, Berlin-New York, 1977 (book review ...https://dspace.library.uu.nl/handle/1874/24893
Clinical features and outcome of multiple primary malignancies involving hepatocellular carcinoma: A long-term follow-up study ...
The last decade has experienced a steady increase in the incidence of MPM . With the expected survival of oncology patients prolonged, it is no longer rare to observe a subsequent primary malignancy in long-term follow-up, especially those from therapy-related carcinogenesis [17, 18]. A recently published paper provided by the Surveillance, Epidemiology and End Results Program estimated 7.9% of cancer-survivors were living with a history of more than one primary malignancy in the U. S . The reported prevalence estimated that cancer-survivors were at an increased risk of being diagnosed with a secondary primary malignancy [19-21]. Bhatia et al. showed the risk of second tumor was increased approximately 18 times in survivors of childhood Hodgkin's lymphoma . The incidence of second neoplasm in cancer-survivors (2.3%, 68/2909) of our center was in accordance with previous literature [6, 16, 22, 23], which was higher than that of the normal ...https://bmccancer.biomedcentral.com/articles/10.1186/1471-2407-12-148
Carcinoma of the large bowel in Singapore--a pathological study. | ScholarBank@NUS
Five hundred and sixty-five cases of large bowel cancer were analysed. There were 8 (1.4%) appendiceal tumours, 296 (52.4%) colonic cancers, 236 (41.8%) rectal cancers, 6 (1.1%) anal cancers and 19 (3.4%) multiple primary cancers of the large bowel. Non-mucinous adenocarcinoma was by far the commonest histological type of large bowel cancer (74.7%). This was followed by mucinous carcinoma (20.7%). Other histological types were relatively uncommon. They included carcinoid tumours (1.8%), signet-ring cell carcinoma (1.5%), squamous cell carcinoma (0.7%), undifferentiated carcinoma (0.4%) and adenosquamous carcinoma (0.2%). The proportion of mucinous carcinoma was greater among the Indians and Malays than among the Chinese. There was a positive correlation between the grade and extent of spread of the tumour. The right colon had greater proportion of poorly differentiated adenocarcinomas than the left colon; this tendency was more evident in females. Mucinous carcinoma tended ...http://scholarbank.nus.edu.sg/handle/10635/108038
Synchronous double primary malignancies of the liver and kidney: A case report
A 42-year-old male patient was referred to the Department of General Surgery of The First Affiliated Hospital of Henan University of Science and Technology (Luoyang, China) in August 2014, presenting with poor appetite and abdominal discomfort in the right upper quadrant for 3 months. In 2004, the patient had been diagnosed with chronic liver disease secondary to hepatitis B at The People's Hospital of Yiyang County (Luoyang, China). In addition, the patient had a previous history of alcohol abuse for 17 years (alcohol intake, 250 g/day) and had smoked for 20 years. There was no remarkable family history. On admission, the vital signs were all within the normal ranges (heart rate, 80 beats/min; normal range, 60-100 beats/min; blood pressure, 130/70 mmHg; normal range, 60/90-80/140 mmHg, body temperature, 36.5°C; normal range, 36-37.3°C and respiration rate, 20 times/min; normal range, 12-20 times/min). The patient was generally in good health and did not exhibit any significant weight loss. On ...https://www.spandidos-publications.com/ol/11/3/2057
Swiss clinical practice guidelines on field cancerization of the skin - Zurich Open Repository and Archive
Actinic keratosis (AK) affects millions of people worldwide, and its prevalence continues to increase. AK lesions are caused by chronic ultraviolet radiation exposure, and the presence of two or more AK lesions along with photodamage should raise the consideration of a diagnosis of field cancerization. Effective treatment of individual lesions as well as field cancerization is essential for good long-term outcomes. The Swiss Registry of Actinic Keratosis Treatment (REAKT) Working Group has developed clinical practice guidelines for the treatment of field cancerization in patients who present with AK. These guidelines are intended to serve as a resource for physicians as to the most appropriate treatment and management of AK and field cancerization based on current evidence and the combined practical experience of the authors. Treatment of AK and field cancerization should be driven by consideration of relevant patient, disease, and treatment factors, and appropriate treatment decisions will ...http://www.zora.uzh.ch/id/eprint/108695/
Synchronous squamous cell carcinoma of the endometrium and endometrioid adenocarcinoma of the ovary.
Abstract BACKGROUND: Synchronous primary endometrial and ovarian cancers are relatively uncommon in general population. The etiology and pathogenesis of this phenomenon remains unc..https://www.omicsonline.org/references/synchronous-squamous-cell-carcinoma-of-the-endometrium-and-endometrioid-adenocarcinoma-of-the-ovary-1376560.html
Cancer Council digital library: Polymorphisms in nucleotide excision repair genes and risk of multiple primary melanoma: the...
Polymorphisms in six genes involved in nucleotide excision repair of DNA were examined in a large population-based case-control study of melanoma. Genotyping was conducted for 2485 patients with a single primary melanoma (controls) and 1238 patients with second or higher order primary melanomas (cases). Patients were ascertained from nine geographic regions in Australia, Canada, Italy and the United States. Positive associations were observed for XPD 312 Asn/Asn versus Asp/Asp [odds ratio (OR) = 1.5, 95% confidence interval (CI) 1.2-1.9] and XPD 751 Gln/Gln versus Lys/Lys (OR = 1.4, 95% CI 1.1-1.7) genotypes and melanoma. The combined XPD Asn (A) 312 + Gln (C) 751 haplotype was significantly more frequent in cases (32%) compared with controls (29%) (P = 0.003) and risk of melanoma increased significantly with one and two copies of the haplotype (ORs 1.2, 95% CI 1.0-1.4, and 1.6, 95% CI 1.2-2.0, trend P = 0.002). No significant associations were observed for HR23B codon 249, ...http://researchpubs.cancercouncil.com.au/cancercounciljspui/handle/1/1346
Squamous cell carcinoma of the liver: metastasis or primary neoplasm? - Semantic Scholar
Semantic Scholar extracted view of 'Squamous cell carcinoma of the liver: metastasis or primary neoplasm?' by Silvia Bondini et al.https://www.semanticscholar.org/paper/Squamous-cell-carcinoma-of-the-liver-metastasis-or-Bondini-Leoni/54bc8689e27eae5682dd99b8a11b860a81aa574b
Differential Diagnosis of the Cancer Family Syndrome. | Annals of Internal Medicine | American College of Physicians
The cancer family syndrome is characterized by  increased occurrences of adenocarcinoma predominantly adenocarcinoma of the colon, stomach, and endometrium;  an excess of multiple primary malignant neoplasms;  early age of onset of cancer; and  probable autosomal dominant inheritance. Eight families studied during the past 8 years showed the above criteria. Analyses were made of all varieties of malignant neoplasms in the kindreds and compared with the prevalence of comparable cancers from the New York State Tumor Registry (exclusive of New York City) and compared similarly with tumor expectations including all the known varieties of hereditary cancers. Cancer ...http://annals.org/aim/article-abstract/686600/differential-diagnosis-cancer-family-syndrome
Synchronous lung and thyroid tumors: a staging dilemma in the PET-CT era | OncologyPRO
Lung cancer is the second most common non-skin malignancy. In a PET-CT-based staging of lung cancer, positive metabolic neck avidity may be considered a metastasis; however, other interpretations may be synchronous tumor or non-malignant avidity. We present nine cases of synchronous lung and thyroid cancer, which do not share common characteristics, and whose concurrent detection affects the patients' treatment and prognosis. ...http://oncologypro.esmo.org/Topics/Endocrine-Cancers/Synchronous-lung-and-thyroid-tumors-a-staging-dilemma-in-the-PET-CT-era
Although some epidemiologic associations for ovarian cancer are established, such as the risk reduction due to parity or oral contraceptive use, the influence of other characteristics like endometriosis and non-steroidal anti-inflammatory use is less clear. Distinguishing categories of ovarian cancer based on shared pathways of development may clarify these associations and further our understanding of the disease. Traditionally, ovarian cancers have been thought to arise from the ovarian surface epithelium. Recent evidence in BRCA1 or 2 mutation carriers showing synchronous tumors in fallopian tubes and potential precursor lesions with p53 signatures that match tumors suggest that some "ovarian" cancers may originate in the fallopian tube. Tumor origin (e.g., ovarian vs. fallopian) may be classified by rigorous pathologic review protocol, including the identification of tubal lesions and p53 signatures, but this is not practical in population-based studies where the needed tissue is not always ...http://cancerpreventionresearch.aacrjournals.org/content/4/10_Supplement/A107
GastroHep News Story
The researchers analyzed the effect of preoperative chemotherapy on short-term and long-term outcome.. The team determined 1 and 3 year survival.. Patients who received neoadjuvant chemotherapy had a higher number of metastases, and more had synchronous tumors.. The researchers found that overall morbidity was 37%, and hospital mortality was 4%.. The research team observed that operative and in-hospital outcome was not influenced by chemotherapy.. The researchers noted that long-term survival was worse in patients who had received preoperative chemotherapy.. Dr Hewes' team concludes, This study shows no evidence that neoadjuvant chemotherapy, and in particular oxaliplatin, increases the risk associated with liver resection for colorectal metastases. Long-term outcome is reduced in patients receiving preoperative chemotherapy, although they have more advanced disease. ...http://www.gastrohep.com/news/news.asp?id=54938
Development of resistance is a significant clinical problem for virtually all targeted cancer therapies. We have generated a reproducible, patient derived xenograft (PDX) model of acquired vemurafenib resistance to address these challenges. Continuous treatment of V600E melanoma tumors, caused synchronous tumor stasis for approximately 7 weeks, following which, all tumors displayed simultaneous resistance marked by rapid tumor growth. Additionally, this model maintains the resistance phenotype upon serial transplantation, providing a platform for testing rational drug selection. The fidelity of the PDX models was further confirmed using a BRAF V600V tumor which did not respond to vemurafenib. Onset of vemurafenib resistance is accompanied by increased phosphor-ERK signifying re-engagement of the MAPK signaling pathway and supporting MEK as a potential target. MEK inhibition in vemurafenib resistant tumors using PD0325901, resulted in rapid tumor shrinkage and dramatically reduced phosphor-ERK ...http://mct.aacrjournals.org/content/12/11_Supplement/B12
Treatment of the primary neoplasm with radiotherapy or chemotherapy is an established risk factor for second neoplasms (SNs) after childhood cancer. As only a small percentage of the treated children suffer from SN, other shared risk factors must be involved. A predisposition for the occurrence of a SN might be a pre-existing somatic genetic defect associated with DNA repair. We investigated the association between gene expression involved in DNA-repair and the development of SNs after childhood cancer. Designed as a feasibility study this project addressed the possibility of obtaining samples for genetic analyses from former patients through the German Childhood Cancer Registry. We recruited 20 patients with two neoplasms (the first occurring in childhood) and 20 matched patients with one neoplasm in childhood. Matching was by first neoplasm, age and year of first diagnosis. Registered SN were confirmed to be no relapses or ...http://cancerres.aacrjournals.org/content/72/8_Supplement/5504
Appendix C: Site Specific Coding Modules - 2013 SEER Coding and Staging Manual
Historical Staging and Coding Manuals. Appendix C brings together the site-specific instructions needed to abstract a case, facilitating efficiency and accuracy. The site-specific coding modules include SEER Coding Guidelines; Equivalent Terms, Definitions, Tables, Charts and Illustrations; Multiple Primary Rules; Histology Coding Rules; Collaborative Stage Coding Instructions1 and Surgery of Primary Site codes2.. General instructions in the main manual are applicable in the absence of site-specific instructions. All modules include the collaborative stage and surgery codes, and multiple primary and histology coding rules. Some modules include site-specific coding guidelines. The goal is to have stand-alone modules for major anatomic sites.. ...https://seer.cancer.gov/archive/manuals/2013/appendixc.html
Appendix C: Site Specific Coding Modules - 2014 SEER Coding and Staging Manual
Historical Staging and Coding Manuals. Appendix C brings together the site-specific instructions needed to abstract a case, facilitating efficiency and accuracy. The site-specific coding modules include SEER Coding Guidelines; Equivalent Terms, Definitions, Tables, Charts and Illustrations; Multiple Primary Rules; Histology Coding Rules; Collaborative Stage Coding Instructions1 and Surgery of Primary Site codes2.. General instructions in the main manual are applicable in the absence of site-specific instructions. All modules include the collaborative stage and surgery codes, and multiple primary and histology coding rules. Some modules include site-specific coding guidelines. The goal is to have stand-alone modules for major anatomic sites.. ...https://seer.cancer.gov/archive/manuals/2014/appendixc.html
Throughput analysis for cognitive radio networks with multiple primary users and imperfect spectrum sensing - IET Journals &...
In cognitive radio networks, the licensed frequency bands of the primary users (PUs) are available to the secondary user (SU) provided that they do not cauhttp://ieeexplore.ieee.org/document/6409524/?reload=true&arnumber=6409524&punumber%3D4105970
A simplicial complex-based approach to unmixing tumor progression data | BMC Bioinformatics | Full Text
Cancer progression is an evolutionary process of successive genetic diversification and selection for mutations promoting tumor growth. While specific sequences of mutations are idiosyncratic to each tumor, functionally similar clusters of mutations are found across many patients in specific genetic pathways that are crucial to promoting tumor growth and invasion and disabling normal checks on cancer development . The recognition that distinct tumors frequently exhibit similar progression pathways led to the idea of cancer phylogenetics (oncogenetics): the use of algorithms for evolutionary tree-building to reconstruct common pathways of evolution in tumors . These methods originally modeled distinct tumors as "species," using heterogeneity between tumors to derive phylogenetic trees providing an inference of common progresion pathways among patients. An alternative approach to tumor phylogenetics arose from the observation that as tumors evolve, they generate heterogeneity between cell ...https://bmcbioinformatics.biomedcentral.com/articles/10.1186/s12859-015-0694-x
ICD-10-CM Section C30-C39
A primary malignant neoplasm that overlaps two or more contiguous (next to each other) sites should be classified to the subcategory/code .8 ('overlapping lesion'), unless the combination is specifically indexed elsewhere. For multiple neoplasms of the same site that are not contiguous, such as tumors in different quadrants of the same breast, codes for each site should be assigned ...https://icd.codes/icd10cm/chapter2/C30-C39
ICD-10-CM Section C43-C44
A primary malignant neoplasm that overlaps two or more contiguous (next to each other) sites should be classified to the subcategory/code .8 ('overlapping lesion'), unless the combination is specifically indexed elsewhere. For multiple neoplasms of the same site that are not contiguous, such as tumors in different quadrants of the same breast, codes for each site should be assigned ...https://icd.codes/icd10cm/chapter2/C43-C44
Rat IgG (H&L) (Heavy and Light chain) - NB7597 | acris-antibodies.com
Rat IgG (H&L), 0.1 mg. This secondary antibody is specifically designed for the detection of multiple primary antibodies (polyclonal or monoclonal) of different host species in experiments where cells are simultaneously labeled without unwanted crosshttps://www.acris-antibodies.com/antibodies/secondary-antibodies/rat-igg-h-l-nb7597.htm
Human IgG (H&L) - NB120-6958 | acris-antibodies.com
Human IgG (H&L), 0.5 mg. This secondary antibody is specifically designed for the detection of multiple primary antibodies (polyclonal or monoclonal) of different host species in experiments where cells are simultaneously labeled without unwanted crosshttps://www.acris-antibodies.com/antibodies/secondary-antibodies/human-igg-h-l-nb120-6958.htm
Rabbit IgG (H&L) - NB120-6941 | acris-antibodies.com
Rabbit IgG (H&L), 0.2 mg. This secondary antibody is specifically designed for the detection of multiple primary antibodies (polyclonal or monoclonal) of different host species in experiments where cells are simultaneously labeled without unwanted crosshttps://www.acris-antibodies.com/antibodies/secondary-antibodies/rabbit-igg-h-l-nb120-6941.htm